p53 suppresses carcinoma progression by inhibiting mTOR pathway activation.
about
mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and agingmTORC1 maintains the tumorigenicity of SSEA-4(+) high-grade osteosarcoma.Hypermethylation of the tumor-suppressor cell adhesion molecule 1 in human papillomavirus-transformed cervical carcinoma cells.Pyruvate Kinase M2 Activates mTORC1 by Phosphorylating AKT1S1Structurally novel steroidal spirooxindole by241 potently inhibits tumor growth mainly through ROS-mediated mechanismsExploiting the yeast stress-activated signaling network to inform on stress biology and disease signaling.Trp53 Mutants Drive Neuroendocrine Lung Cancer through Loss-of-Function Mechanisms with Gain-of-Function Effects on Chemotherapy Response.The NAD+ synthesizing enzyme nicotinamide mononucleotide adenylyltransferase 2 (NMNAT-2) is a p53 downstream targetSelective Ablation of Tumor Suppressors in Parafollicular C Cells Elicits Medullary Thyroid Carcinoma.Autophagy inhibition enhances RAD001-induced cytotoxicity in human bladder cancer cells.p16 controls epithelial cell growth and suppresses carcinogenesis through mechanisms that do not require RB1 function.MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomassiRNA targeting RBP2 inhibits expression, proliferation, tumorigenicity and invasion in thyroid carcinoma cellsExpression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma.Preclinical Imaging for the Study of Mouse Models of Thyroid Cancer.Colorectal carcinomas with submucosal invasion (pT1): analysis of histopathological and molecular factors predicting lymph node metastasis.p53 and metabolism: from mechanism to therapeutics.
P2860
Q28081442-25FFB0FE-2F93-4C33-9F83-F4E2C1ABA161Q35319234-3BCD6849-9BFB-46BD-985F-AB50A4874279Q35636451-181D0F68-79CF-4831-A72D-61C89B59A1EFQ36579508-058F1684-C93B-4FDF-B49D-C3739AE075A9Q37177557-FB8631E4-0442-4C21-B498-7D7BFB8DA1A1Q38468872-EEF2FF98-B441-43E4-9593-92BAEFD5DFCCQ38605143-FAAE79F0-45A9-4F1F-9B55-E0C46116F5D9Q38717667-BDCAC1B1-4F82-40F4-8567-2F7819661C61Q38719594-A9269AA0-A46B-4B5A-BCCA-D03EA54688E0Q40510800-E6B5E5F9-CB3A-4EE3-8270-47B8DE5598F7Q41080919-3C00674F-C1A1-4020-9EB3-305207C8D440Q41553688-1835F7BF-09E1-468F-B6A2-0D1576545638Q41976557-3FF3503B-1664-4110-A945-4C58C6D01A27Q46513952-91754620-4923-476A-9214-CDC8FFF72AF2Q49475238-A352354E-11EC-4927-8B02-F042EDD9FB0BQ54171582-67870457-67C5-405D-A774-FF300F7C8620Q55002919-50714737-C6D4-4DE2-9363-5E79F372DC31
P2860
p53 suppresses carcinoma progression by inhibiting mTOR pathway activation.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
p53 suppresses carcinoma progression by inhibiting mTOR pathway activation.
@en
p53 suppresses carcinoma progression by inhibiting mTOR pathway activation.
@nl
type
label
p53 suppresses carcinoma progression by inhibiting mTOR pathway activation.
@en
p53 suppresses carcinoma progression by inhibiting mTOR pathway activation.
@nl
prefLabel
p53 suppresses carcinoma progression by inhibiting mTOR pathway activation.
@en
p53 suppresses carcinoma progression by inhibiting mTOR pathway activation.
@nl
P2093
P2860
P356
P1433
P1476
p53 suppresses carcinoma progression by inhibiting mTOR pathway activation.
@en
P2093
A L Miller
K A Wikenheiser-Brokamp
P2860
P2888
P304
P356
10.1038/ONC.2013.589
P407
P577
2014-01-27T00:00:00Z